-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
1.
lung cancer
For non-small cell lung cancer ( NSCLC ) patients without driver mutations, chemotherapy remains the cornerstone of antitumor therapy
NSCLC
The classic first-line regimen for NSCLC is platinum-containing two drugs
For lung adenocarcinoma, pemetrexed + cisplatin is usually chosen
Also combined with platinum, paclitaxel liposome has comparable efficacy to paclitaxel, with better safety and tolerability, and lower peripheral neuritis
For patients with no disease progression, good physical status, and tolerable adverse reactions after 4-6 cycles of first-line treatment, single-agent maintenance therapy can be considered
Second-line chemotherapy was given to patients with a PS score of 0-2.
Etoposide in combination with cisplatin or carboplatin is the standard regimen for first-line therapy
-
For SCLC that recurs more than 6 months after first-line treatment, the original first-line regimen can be used again for patients who are more sensitive to first-line treatment
-
For patients whose recurrence time is less than 6 months, second-line drug switching should be considered; single drugs include: topotecan, irinotecan, gemcitabine, paclitaxel, docetaxel, temozolomide,
For SCLC that recurs more than 6 months after first-line treatment, the original first-line regimen can be used again for patients who are more sensitive to first-line treatment
For SCLC that recurs more than 6 months after first-line treatment, the original first-line regimen can be used again for patients who are more sensitive to first-line treatment
For patients whose recurrence time is less than 6 months, second-line drug switching should be considered; single drugs include: topotecan, irinotecan, gemcitabine, paclitaxel, docetaxel, temozolomide,
For patients whose recurrence time is less than 6 months, second-line drug switching should be considered; single drugs include: topotecan, irinotecan, gemcitabine, paclitaxel, docetaxel, temozolomide,
2.
2.
Combination chemotherapy is preferred for symptomatic or visceral metastases requiring rapid remission
.
When choosing combination chemotherapy, it is necessary to weigh the efficacy and adverse effects
.
For patients with advanced breast cancer with tumor burden and no obvious symptoms, single-agent chemotherapy can be given priority;
For patients with advanced breast cancer with tumor burden and no obvious symptoms, single-agent chemotherapy can be given priority;
Combination chemotherapy is preferred for symptomatic or visceral metastases requiring rapid remission
.
When choosing combination chemotherapy, it is necessary to weigh the efficacy and adverse effects
.
Combination chemotherapy is preferred for symptomatic or visceral metastases requiring rapid remission
.
When choosing combination chemotherapy, it is necessary to weigh the efficacy and adverse effects
.
3.
Colorectal cancer
Colorectal cancer Colorectal cancer
4.
Gastric cancer
leave a message here